| |
Baseline (mean ± s.d)
|
24 weeks (mean ± s.d)
|
Mean changes from baseline (95% CI)
| ★Difference in mean change (95% CI) |
ΔDifference in mean change (95% CI)
|
|---|
|
HbA1c (%)
|
|
Vildagliptin
|
8.75 ± 1.15
|
7.41 ± 1.43
|
-1.34 (-2.03, -0.64)**
| | |
|
Saxagliptin
|
8.86 ± 1.13
|
7.65 ± 1.41
|
-1.21 (-1.91, -0.51)**
|
0.13 (-0.66, 0.40)
| |
|
Sitagliptin
|
8.54 ± 1.19
|
7.47 ± 1.42
|
-1.07 (-1.64, -0.50)**
|
0.27 (-0.80, 0.26)
|
0.14 (-0.67, 0.39)
|
|
FBG (mmol/L)
|
|
Vildagliptin
|
8.79 ± 1.80
|
6.35 ± 1.57
|
-2.44 (-3.01, -1.87)**
| | |
|
Saxagliptin
|
8.36 ± 2.04
|
6.53 ± 1.92
|
-1.83 (-2.13, -1.53)**
|
0.61 (0.30, 0.92)##
| |
|
Sitagliptin
|
8.22 ± 1.77
|
6.73 ± 1.69
|
-1.49 (-1.69, -1.29)**
|
0.95 (0.64, 1.26)##
|
0.34 (0.03, 0.65)Δ
|
|
P2BG (mmol/L)
|
|
Vildagliptin
|
11.98 ± 2.46
|
8.27 ± 2.28
|
-3.71 (-4.16, -3.26)**
| | |
|
Saxagliptin
|
11.77 ± 3.07
|
8.36 ± 2.70
|
-3.41 (-4.33, -2.49)**
|
0.30 (-0.32, 0.92)
| |
|
Sitagliptin
|
10.98 ± 2.93
|
7.82 ± 2.58
|
-3.16 (-4.03, -2.29)**
|
0.55 (-0.07, 1.17)
|
-0.25 (-0.37, 0.87)
|
- 63 subjects in Vildagliptin-added group, 66 subjects in Saxagliptin-added group and 61 subjects in Sitagliptin-added group were analyzed; ★Difference in mean change calculated as Saxagliptin minus Vildagliptin or Sitagliptin minus Vildagliptin; ΔDifference in mean change calculated as Sitagliptin minus Saxagliptin. CI: confidence interval; **p < 0.01 for mean change from baseline in Vildagliptin, Saxagliptin and Sitagliptin; ##p < 0.01 for the between-treatment difference from Vildagliptin; Δp < 0.05, ΔΔp < 0.01 for the between-treatment difference from Saxagliptin.
